# US 2012/0251631 A1 · Methods of treating or preventing peritonitis with oxidative reductive potential water solution

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251631 A1
- Document ID: US20120251631A1
- Status: Published application
- Kind: A1
- Application number: 13/436,288
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2006-01-20
- Assignees: Oculus Innovative Sciences, Inc.
- Inventors: Hojabr ALIMI; Andres Gutierrez
- Web page: https://patentgrep.com/patent/US20120251631A1

## CPC

- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/40: Peroxides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/20: for DNA viruses
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided is a method for treating or preventing peritonitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents. Further provided is a method for preventing peritoneal hemorrhage, adhesions and abscesses.

## Claims

### Claim 1

A method of preventing or treating peritonitis in a patient, the method comprising administering to the patient a therapeutically effective amount of an oxidative reductive potential water solution, wherein the solution comprises free chlorine species at a level of from about 10 ppm to about 200 ppm, wherein the solution is stable for at least two months, wherein the solution comprises anode water and cathode water, and wherein the solution has a pH of from about 6.4 to about 7.8.

### Claim 2 (depends on 1)

The method of claim 1, comprising contacting the peritoneal tissue in the patient with a therapeutically effective amount of the oxidative reductive potential water solution.

### Claim 3 (depends on 1)

The method of claim 1, comprising delivering a therapeutically effective amount of the oxidative reductive potential water solution to the patient's peritoneal space.

### Claim 4 (depends on 3)

The method of claim 3, wherein the oxidative reductive potential water solution is delivered to the patient's peritoneal space intra-operatively, laproscopically or transabdominally.

### Claim 5 (depends on 3)

The method of claim 3, comprising:
(a) gaining access to the peritoneal space in the patient;
(b) delivering to the peritoneal space from about 0.1 to about 10 L of the oxidative reductive potential water solution;
(c) allowing the oxidative reductive potential water solution to remain in the peritoneal space for a period of time sufficient to provide a therapeutic effect;
(d) optionally removing the oxidative reductive potential water solution; and
(e) optionally repeating steps (b)-(d).

### Claim 6 (depends on 1)

The method of claim 1, wherein the peritonitis results from surgery, appendicitis, acute cholecystitis, peptic ulcer, diverticulitis, bowel obstruction, pancreatitis, pelvic inflammatory disease, mesenteric thrombosis, tumor, penetrating trauma, or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the peritonitis is associated with an infection by one or more microorganisms selected from the group consisting of viruses, bacteria, and fungi.

### Claim 8 (depends on 7)

The method of claim 7, wherein the infection is by one or more bacteria selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli, Enterococcus hirae, Acinetobacter baumannii, Acinetobacter species, Bacteroides fragilis, Enterobacter aerogenes, Enterococcus faecalis, Vancomycin resistant-Enterococcus faecium (VRE, MDR), Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Micrococcus luteus, Proteus mirabilis, Serratia marcescens, Staphylococcus aureus, Methicilin resistant-Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, Salmonella choleraesuis, Shigella dysenteriae, C. perfingens, Neisseria gonorrhea, Chlamydia trachomatis, Mycobaterium bovis, Chlamydia trachomatis, and combinations thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the infection is by one or more fungi selected from the group consisting of Candida albicans, Candida parapsilasis, Candida tropicalis, Trichophyton mentagrophytes and Aspergillus fumigaus.

### Claim 10 (depends on 1)

The method of claim 1, further comprising administering to the patient a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of anti-infective agents and anti-inflammatory agents.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pH of the oxidative reductive potential water solution is from about 7.4 to about 7.6.

### Claim 12 (depends on 1)

The method of claim 1, wherein the oxidative reductive potential water solution comprises cathode water in an amount of from about 10% to about 50% by volume of the solution, and anode water in an amount of from about 50% to about 90% by volume of the solution.

### Claim 13 (depends on 1)

The method of claim 1, wherein the solution comprises free chlorine species at a level of from about 50 ppm to about 80 ppm

### Claim 14 (depends on 1)

The method of claim 1, wherein the free chlorine species is selected from the group selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, chloride ions, dissolved chlorine gas, and mixtures thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the free chlorine species comprises from about 15 ppm to about 35 ppm hypochlorous acid.

### Claim 16 (depends on 1)

The method of claim 1, wherein the free chlorine species comprises from about 25 ppm to about 50 ppm sodium hypochlorite.

### Claim 17 (depends on 1)

The method of claim 1, wherein the free chlorine species comprises from about 15 ppm to about 35 ppm hypochlorous acid and from about 25 ppm to about 50 ppm sodium hypochlorite.

### Claim 18

A method of preventing peritoneal adhesions in a patient, the method comprising administering to the patient an oxidative reductive potential water solution in an amount effective to prevent peritoneal adhesions, wherein the solution comprises free chlorine species at a level of from about 10 ppm to about 200 ppm, wherein the solution is stable for at least two months, wherein the solution comprises anode water and cathode water, and wherein the solution has a pH of from about 6.4 to about 7.8.

### Claim 19

A method of preventing peritoneal abscesses in a patient, the method comprising administering to the patient an oxidative reductive potential water solution in an amount effective to prevent peritoneal abscesses, wherein the solution comprises free chlorine species at a level of from about 10 ppm to about 200 ppm, wherein the solution is stable for at least two months, wherein the solution comprises anode water and cathode water, and wherein the solution has a pH of from about 6.4 to about 7.8.

### Claim 20

A method of preventing systemic complications in a patient with peritonitis, the method comprising administering to the patient an oxidative reductive potential water solution in an amount effective to prevent peritoneal adhesions, wherein the solution comprises free chlorine species at a level of from about 10 ppm to about 200 ppm, wherein the solution is stable for at least two months, wherein the solution comprises anode water and cathode water, and wherein the solution has a pH of from about 6.4 to about 7.8.
